Every 8-K that Alamar Biosciences, Inc. (ALMR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ALMR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALMR filings page.
Alamar Biosciences, Inc. (ALMR) reported that its board of directors appointed Robert Ragusa to the board effective September 1, 2026. He will serve as a Class I Director with an initial term expiring at the company’s 2027 Annual Meeting of Stockholders.
Ragusa was also appointed to the board’s Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee. He will receive compensation under the company’s Non-Employee Director Compensation Policy and will enter into its standard indemnification agreement. The company states there were no arrangements leading to his selection and no related person transactions requiring disclosure.
Alamar Biosciences, Inc. reported strong growth for the quarter ended June 30, 2026. Total revenue was $29.4 million, up 82% from $16.2 million a year earlier. Instruments contributed $7.8 million, consumables $15.5 million, and services and other revenue $6.2 million, with consumable revenue rising 147% year-over-year on demand for multiplex panels. Gross margin improved to 60% from 53%, driven by manufacturing efficiencies and a revenue mix shift toward higher-margin consumables.
Operating expenses increased to $31.2 million, up 89% from $16.5 million, reflecting higher headcount, infrastructure, R&D investments and public company costs. Operating loss widened to $13.5 million from $7.9 million, and net loss was $13.2 million versus $7.0 million, with net loss per share of $(0.22) compared with $(0.62). Cash, cash equivalents, short-term investments and restricted cash totaled $256.3 million as of June 30, 2026. For full year 2026, the company forecasts revenue of $116–$120 million, representing 59% growth at the midpoint over 2025.
Alamar Biosciences, Inc. reported that board member Ian Ratcliffe, an independent director since February 2024, passed away on July 5, 2026. The company expressed condolences and acknowledged his dedication and service.
Following his passing, the board reduced the authorized number of directors constituting the full board to five and appointed Nicholas Naclerio, Ph.D., to the Audit Committee of the board.
Alamar Biosciences, Inc. reported first quarter 2026 results showing rapid growth but continuing losses. Total revenue reached $26.0 million, up 99% from $13.1 million a year earlier, driven by strong instrument, consumable, and services demand.
Instrument revenue rose to $7.4 million, consumables to $14.0 million, and services and other to $4.7 million. Gross margin improved to 56% from 49% on higher volumes and a mix shift toward consumables. Operating expenses increased to $26.8 million, leading to an operating loss of $12.3 million.
Net loss widened to $21.3 million, including an $8.6 million loss on remeasurement of convertible notes. Cash, cash equivalents and restricted cash totaled $69.5 million as of March 31, 2026. After quarter end, Alamar completed its initial public offering, raising $197.8 million of net proceeds to strengthen its balance sheet.
Alamar Biosciences, Inc. completed its initial public offering of common stock on April 20, 2026. The company sold 12,937,500 shares, including 1,687,500 shares from the full exercise of the underwriters’ option, at $17.00 per share, generating approximately $219.9 million in gross proceeds before fees and expenses.
Immediately before the IPO closing, Alamar implemented an amended and restated certificate of incorporation and amended and restated bylaws, previously approved by its board and stockholders, to establish its post‑IPO corporate governance framework.